Protagonist Therapeutics Inc Stock News

Related Stocks: RCUS , GRTS , RNA , NRIX , DSGN , ODT , GLPG , PTGX , TNGX , ERAS , IMVT , BLUE , TBIO , KYMR , ARVN , BCEL , KDNY , ZNTL ,

NEWARK, Calif., Nov. 11, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Following huge swings over the last two months, the biotech stock is now up 67% year to date.

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -4.48% and 199.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A short squeeze can occur

Here are five short squeeze stocks many investors are putting on their radar right now as a result of higher short interest and borrow fees. The post Short Squeeze Stocks: PTGX, AGC and 3 Others Exper

ARNC, BSET, FMS, OCUL, and PTGX have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2021.

Solar stocks are on the move today and that's good news for investors as shares are shining brighter on energy shortage news. The post Solar Stocks: Why SUNW, SPWR, DQ, ENPH and SEDG Are Shining Brigh

Shares of Protagonist Therapeutics Inc (NASDAQ: PTGX) nearly doubled on Monday as the U.S. FDA said it could resume the clinical trials for Rusfertide – an investigational, injectable hepcidin mimet

Protagonist Therapeutics (PTGX) stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies. The post PTGX Stock: The FDA News That Has Protagonist Ther

The stock price of Protagonist Therapeutics Inc (NASDAQ: PTGX) increased by over 80% pre-market today. This is why it happened.

Shares of Protagonist Therapeutics Inc. PTGX, +0.72% soared 87.0% in premarket trading on Monday after the company said the Food and Drug Administration had lifted a clinical hold on clinical trials o

NEWARK, Calif., Oct. 11, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that the U.S. Food and Drug Administration (FDA) has remov

When Wall Street overreacts to a news catalyst, contrarian traders can step in to take advantage of a rare opportunity now with PTGX stock. The post Battered Protagonist Therapeutics Stock Is Primed F

NEWARK, Calif., Oct. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that an abstract highlighting new results from its Phase 2